- $445.91m
- $387.58m
- $180.46m
NASDAQ RESUMED
Brief: Kamada announces FDA acceptance of Inhaled AAT program path forward
NASDAQ TRADE HALT HALT NEWS PENDING
Brief: Kamada Reports Financial Results For Fourth Quarter And FY2018
Brief: Kamada Announces Additional Interim Results From Phase 2 Proof Of Concept Clinical Trial Of Intravenous Alpha-1 Antitrypsin Treatment
Brief: Kamada Sees FY 2019 Revenue Of $125 Million To $130 Million
Brief: Kamada Q3 Loss Per Share $0.06
Brief: Kitov Appoints Gil Efron As Deputy CEO And CFO
Brief: Kamada Announces Extension Of Collaboration With Massachusetts General Hospital
U.S. STOCKS ON THE MOVE-Amazon, Alphabet, Tiffany, Glaukos, Square, Box
U.S. STOCKS ON THE MOVE-Amazon, Alphabet, Tiffany, Glaukos, American Eagle, iPass
U.S. STOCKS ON THE MOVE-Under Armour, Royal Caribbean, Glaukos, American Eagle
U.S. STOCKS ON THE MOVE-Under Armour, Royal Caribbean, Glaukos, American Eagle
U.S. STOCKS ON THE MOVE-Amazon, Glaukos, Dick's Sporting, Yirendai, Tilray, Box Inc
Brief: Kamada Announces End Of Labor Strike In Company's Manufacturing Facility
Brief: Kamada Q2 Earnings Per Share $0.14
Brief: Kamada Receives Positive Scientific Advice From European Medicines Agency
Brief: Kamada Reports Q1 Earnings Per Share $0.03
Brief: Kamada Ltd Says Kedrab Has Been Launched In U.S.